PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34882770-2	2021	Efavirenz is primarily metabolized by cytochrome P450 2B6 (CYP2B6), with CYP2A6 as an accessory pathway.	efavirenz	0-9	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	73-79	
34882770-6	2021	Genetic polymorphisms known to be associated with increased efavirenz plasma concentrations in CYP2B6 (rs3745274, rs28399499, rs4803419) and CYP2A6 (rs28399433) were selected and used to determine proportions of slow metabolizers.	efavirenz	60-69	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	141-147	
24820076-0	2014	Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.	efavirenz	71-80	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	155-161	
30535366-8	2019	CYP2A6 -48A C was independently associated with higher CSF 8-hydroxy-efavirenz:efavirenz ratio (beta = 0.54, P = 0.048).	efavirenz	69-78	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	0-6	
26288843-4	2015	METHODS: We genotyped CYP2A6, CYP2B6 and CYP3A4, which encode enzymes principally involved in EFV metabolism, from patients enrolled in the multinational SMART, FIRST and ESPRIT studies, for whom outcome data of treatment adherence was available.	efavirenz	94-97	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	22-28	
26288843-8	2015	FINDINGS: Patients with highest pharmacogenetic risk, as defined by cumulative SNPs in CYP2A6, CYP2B6 and CYP3A4, have an increased risk of discontinuation of EFV containing therapy compared to patients with lower genetic risk scores (adjusted HR 1.9, 95% CI 1.2, 3.1, P = 0.009).	efavirenz	159-162	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	87-93	
24316028-6	2014	Predictive factors of EFV plasma levels in the presence of rifampicin-based TB treatment were CYP2A6 1093G>A, CYP2B6 516G>T, and CYP2B6 983T>C accounting for 27%, 43%, and 29% of the total variance in EFV levels, respectively.	efavirenz	22-25	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	94-100	
19371316-10	2009	Multiple linear regression analysis indicated that the CYP2B6 c.516G-->T polymorphism and CYP2A6 slow-metabolizing variants accounted for as much as 36 and 12% of the total variance in efavirenz concentrations, respectively.	efavirenz	188-197	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	93-99